|
|
Treatment Algorithms 2001: AsthmaPublished by: Datamonitor Published: Jan. 3, 2002 - 237 Pages Table of ContentsDATAMONITOR HEALTHCARE CONTACT DETAILS Scope Datamonitor Insight into the Asthma Market Key Metrics COMPARATIVE ANALYSIS Epidemiology Disease Awareness Diagnosis Symptoms Triggers and Co-morbidities Physicians Involved in Treating Asthma Presentation Diagnosis Treatment Treatment Practices Treatment guidelines Pharamcological versus non-pharamcological therapy Symptomatic versus maintenance therapy Drug classes used as initial therapy Second line therapy Generic versus Branded Prescribing Compliance Unmet Needs ASTHMA IN THE US Treatment Tree Epidemiology Disease awareness Screening Diagnosis Physicians involved in presentation and diagnosis Symptoms and triggers Diagnostic tests Co-morbidities of asthma Treatment of Asthma Physicians involved in the treatment of Asthma Treatment guidelines Pharmacological versus non-pharmacological therapy Symptomatic and maintenance therapy Drug classes used in first line treatment Beta2-agonists (inhaled) Beta2-agonists (oral) Corticosteroids (inhaled) Corticosteroids (oral) Xanthines Leukotriene antagonists Anticholinergics Mast cell inhibitors Combination products Second line treatment Treatment outcomes Referrals Branded versus generic prescribing Compliance Future Focus Unmet needs Prevalence Diagnosis Awareness Prescribing restrictions ASTHMA IN JAPAN Treatment Tree Epidemiology Disease awareness Screening Diagnosis Physicians involved in presentation and diagnosis Symptoms and triggers Diagnostic tests Co-morbidities of asthma Treatment of Asthma Physicians involved in treating Asthma Treatment guidelines Pharmacological versus non-pharmacological therapy Symptomatic and maintenance therapy Drug classes used in first line treatment Beta2-agonists (inhaled) Beta2-agonists (oral) Beta2-agonists (other) Corticosteroids (inhaled) Corticosteroids (oral) Corticosteroids (other) Xanthines Leukotriene antagonists Anticholinergics Mast cell inhibitors Second line treatment Treatment outcomes Referrals Branded versus generic prescribing Compliance Future Focus Unmet needs Prevalence Diagnosis Awareness Prescribing restrictions ASTHMA IN FRANCE Treatment Tree Epidemiology Disease awareness Screening Diagnosis Physicians involved in presentation and diagnosis Symptoms and triggers Diagnostic tests Co-morbidities of asthma Treatment of Asthma Physicians involved in the treatmentment of Asthma Treatment guidelines Pharmacological versus non-pharmacological therapy Symptomatic and maintenance therapy Drug classes used in first line treatment Beta2-agonists (inhaled) Beta2-agonists (oral) Corticosteroids (inhaled) Corticosteroids (oral) Xanthines Leukotriene antagonists Anticholinergics Mast cell inhibitors Combination products Second line treatment Treatment outcomes Referrals Branded versus generic prescribing Compliance Future Focus Unmet needs Prevalence Diagnosis Awareness Prescribing restrictions ASTHMA IN GERMANY Treatment Tree Epidemiology Disease awareness Screening Diagnosis Physicians involved in presentation and diagnosis Symptoms and triggers Diagnostic tests Co-morbidities of asthma Treatment of Asthma Physicians involved in the treatment of Asthma Treatment guidelines Pharmacological versus non-pharmacological therapy Symptomatic and maintenance therapy Drug classes used in first line treatment Beta2-agonists (inhaled) Beta2-agonists (oral) Corticosteroids (inhaled) Corticosteroids (oral) Xanthines Leukotriene antagonists Anticholinergics Mast cell inhibitors Combination products Second line treatment Treatment outcomes Referrals Branded versus generic prescribing Compliance Future Focus Unmet needs Prevalence Diagnosis Awareness Prescribing restrictions ASTHMA IN ITALY Treatment Tree Epidemiology Disease awareness Screening Diagnosis Physicians involved in presentation and diagnosis Symptoms and triggers Diagnostic tests Co-morbidities of asthma Treatment of Asthma Physicians involved with treatment Treatment guidelines Pharmacological versus non-pharmacological therapy Symptomatic and maintenance therapy Drug classes used in first line treatment Beta2-agonists (inhaled) Beta2-agonists (oral) Corticosteroids (inhaled) Corticosteroids (oral) Xanthines Leukotriene antagonists Anticholinergics Mast cell inhibitors Combination products Second line treatment Treatment outcomes Referrals Branded versus generic prescribing Compliance Future Focus Unmet needs Prevalence Diagnosis Awareness Prescribing restrictions ASTHMA IN SPAIN Treatment Tree Epidemiology Disease awareness Screening Diagnosis Physicians involved in presentation and diagnosis Symptoms and triggers Diagnostic tests Co-morbidities of asthma Treatment of Asthma Physicians involved with treatment Treatment guidelines Pharmacological versus non-pharmacological therapy Symptomatic and maintenance therapy Drug classes used in first line treatment Beta2-agonists (inhaled) Beta2-agonists (oral) Corticosteroids (inhaled) Corticosteroids (oral) Xanthines Leukotriene antagonists Anticholinergics Mast cell inhibitors Combination products Second line treatment Treatment outcomes Referrals Branded versus generic prescribing Compliance Future Focus Unmet needs Prevalence Diagnosis Awareness Prescribing restrictions ASTHMA IN THE UK Treatment Tree Epidemiology Disease awareness Screening Diagnosis Physicians involved in presentation and diagnosis Symptoms and triggers Diagnostic tests Co-morbidities of asthma Treatment of Asthma Physicians involved with treatment Treatment guidelines Pharmacological versus non-pharmacological therapy Symptomatic and maintenance therapy Drug classes used in first line treatment Beta2-agonists (inhaled) Beta2-agonists (oral) Corticosteroids (inhaled) Corticosteroids (oral) Xanthines Leukotriene antagonists Anticholinergics Mast cell inhibitors Combination products Second line treatment Treatment outcomes Referrals Branded versus generic prescribing Compliance Future Focus Unmet needs Prevalence Diagnosis Awareness Prescribing restrictions APPENDIX Datamonitor's Immune Disorders and Inflammation Business Unit Contributing experts Bibliography Physician research methodology Introduction Hypothesis formulation Physician recruitment Hypothesis testing Validation and quality control Sample Questionnaire Patient numbers Presentation Screening Diagnosis Treatment First Line Treatment Second Line Treatment Treatment Outcome Generic versus branded prescribing Compliance Referrals Future List of Tables List of Figures (c) Datamonitor 2002. All Rights Reserved. AbstractAsthma is one of the most common chronic disorders in Western and developing countries, the prevalence of which has almost tripled in the last three decades. Asthma remains a severely disabling and life threatening disease for many sufferers despite the availability of effective treatments, owing to low levels of disease awareness amongst both patients and physicians, leading to under estimation of disease severity and sub-optimal disease management. Furthermore, up to a half of all sufferers remain undiagnosed in countries such as the US representing a considerable untapped patient potential.Over the next ten years heightened efforts to reduce the heavy burden asthma places on a country’s healthcare expenditure, coupled with the wider availability of generic products, will result in a shift in physician prescribing patterns, creating a need for more effective and targeted marketing strategies to guarantee the success of any new products launched. This report provides an integrated look at asthma care, covering all aspects of management including: * a thorough analysis of the key drivers of presentation, diagnosis and treatment rates, as well as patient compliance, including the factors influencing awareness of the disease amongst both physicians and the public. * identification of the most commonly used drug classes in each country, a breakdown of the most widely employed brands and key factors influencing physician treatment choices, as well as identification of the current unmet needs of asthma therapy. * analysis of the key factors influencing physician prescribing over the next seven years (2001-2008), including changes in disease understanding, major patent expiries and future changes in treatment practices. Country Coverage: US, Japan, France, Germany, Italy, Spain, UK Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||